Resolution Bioscience Collaborates with Janssen to Develop Cell-Free DNA CDx for Niraparib to Treat Prostate Cancer

Resolution Bioscience Collaborates with Janssen to Develop Cell-Free DNA CDx for Niraparib to Treat Prostate Cancer

Shots:

  • Janssen and Resolution Bioscience develops Resolution’s HRD liquid biopsy test as a companion diagnostic for Janssen’s Niraparib, being investigated for the treatment of metastatic castration-resistant prostate cancer
  • The Resolution HRD assay will allow Janssen to identify patients with prostate cancer who may benefit from Niraparib therapy. In 2016, Janssen got exclusive WW license from Tesaro for Niraparib in prostate cancer
  • The Resolution’s liquid biopsy test detects HRD mutations & gene deletions, being evaluated in P-II & P-III studies of Niraparib in PC and has received FDA’s BT designation on May 30, 2019

Click here to read full press release/ article | Ref: Resolution Bio | Image: PRweb